iifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Lupin zooms ~2% on gaining USFDA approval for hypertension drug

15 Jan 2024 , 02:32 PM

The Lupin share price rose in early trading on January 15 after the pharmaceutical firm received clearance from the United States Food and medicine Administration to launch a generic hypertension medicine.

At around 2.12 PM, Lupin was trading 1.65% higher at Rs 1,420.75 per piece, against the previous close of Rs 1,397.75 on NSE.

Lupin has obtained approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Propranolol Hydrochloride Extended-Release Capsules USP in 60 mg, 80 mg, 120 mg, and 160 mg. 

This approval allows the pharmaceutical company to introduce a generic alternative to ANI Pharmaceuticals, Inc.'s Inderal LA Extended-Release Capsules in corresponding strengths, as stated in the company's official statement.

The drug maker will manufacture the product at its facility situated in Pithampur, India.

Propranolol hydrochloride extended-release capsules. USP are approved for the treatment of hypertension, angina, and the prevention of frequent migraine headaches.

Earlier this month, the business introduced bromfenac pphthalmic solution to treat postoperative inflammation and reduce eye discomfort in cataract surgery patients.

For feedback and suggestions, write to us at editorial@iifl.com

explored-media

Related Tags

  • Lupin
  • Lupin Approval
  • Lupin News
  • Lupin Updates
  • Lupin USFDA
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Most Read News

Indian markets end the day on high
23 May 2024|03:59 PM
Markets surge

Markets surge

Whatsapp
Facebook
Twitter
LinkedIn
23 May 2024|03:45 PM
MG Motor India to supply 3000 EVs to Vertelo
23 May 2024|03:46 PM
Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.